Edwards Lifesciences Co. (NYSE:EW) Stake Increased by Wedmont Private Capital

Wedmont Private Capital increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,189 shares of the medical research company’s stock after buying an additional 405 shares during the quarter. Wedmont Private Capital’s holdings in Edwards Lifesciences were worth $762,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of EW. Kestra Advisory Services LLC lifted its position in shares of Edwards Lifesciences by 26.3% in the third quarter. Kestra Advisory Services LLC now owns 20,181 shares of the medical research company’s stock worth $1,398,000 after buying an additional 4,201 shares during the last quarter. FMR LLC grew its holdings in Edwards Lifesciences by 61.1% during the third quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock valued at $215,557,000 after purchasing an additional 1,179,637 shares during the last quarter. Dark Forest Capital Management LP bought a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $1,780,000. LPL Financial LLC lifted its stake in shares of Edwards Lifesciences by 2.4% in the third quarter. LPL Financial LLC now owns 302,141 shares of the medical research company’s stock worth $20,932,000 after buying an additional 6,980 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $296,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the transaction, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of Edwards Lifesciences stock in a transaction on Monday, May 6th. The shares were purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 127,104 shares of company stock worth $11,267,464. Insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Piper Sandler lifted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Wells Fargo & Company upped their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Citigroup raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $98.00 to $105.00 in a report on Wednesday, May 22nd. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $86.00 to $103.00 in a report on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $95.06.

Get Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Price Performance

NYSE EW traded up $1.66 on Friday, hitting $90.50. 1,496,704 shares of the company were exchanged, compared to its average volume of 3,391,502. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The company has a market cap of $54.54 billion, a P/E ratio of 38.30, a P/E/G ratio of 3.24 and a beta of 1.11. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The firm has a 50 day moving average of $87.45 and a two-hundred day moving average of $84.28.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.